Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2022 — Today, Novartis announced…